Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Assets Average: 2011-2025

Historic Assets Average for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $1.4 billion.

  • Ani Pharmaceuticals' Assets Average rose 24.59% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 24.59%. This contributed to the annual value of $1.1 billion for FY2024, which is 31.46% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Assets Average stood at $1.4 billion for Q3 2025, which was up 4.39% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Assets Average ranged from a high of $1.4 billion in Q3 2025 and a low of $462.5 million during Q1 2021.
  • Its 3-year average for Assets Average is $1.0 billion, with a median of $917.6 million in 2024.
  • In the last 5 years, Ani Pharmaceuticals' Assets Average dropped by 1.49% in 2021 and then soared by 63.93% in 2022.
  • Ani Pharmaceuticals' Assets Average (Quarterly) stood at $621.0 million in 2021, then grew by 20.70% to $749.6 million in 2022, then grew by 19.69% to $897.2 million in 2023, then skyrocketed by 43.29% to $1.3 billion in 2024, then rose by 24.59% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.3 billion during Q1 2025.